Authors' Reply to Pande et al. Comment on "Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder"
CNS Drugs
.
2023 Oct;37(10):939-940.
doi: 10.1007/s40263-023-01035-2.
Epub 2023 Sep 1.
Authors
Maxwell Z Price
1
,
Richard L Price
2
Affiliations
1
Hackensack Meridian School of Medicine, Nutley, NJ, 07110, USA. mzp2103@columbia.edu.
2
Department of Psychiatry, Weill Cornell Medical College, New York, NY, USA.
PMID:
37656357
PMCID:
PMC10570209
DOI:
10.1007/s40263-023-01035-2
No abstract available
Publication types
Letter